Department of Physiotherapy, The University of Melbourne, Melbourne, VIC, Australia.
School of Health Sciences and Social Work, Griffith University, Brisbane, QLD, Australia.
Clin Rheumatol. 2023 Sep;42(9):2267-2278. doi: 10.1007/s10067-023-06654-0. Epub 2023 Jun 9.
Systematic r eview to evaluate the quality of the clinical practice guidelines (CPG) for rheumatoid arthritis (RA) management and to provide a synthesis of high-quality CPG recommendations, highlighting areas of consistency, and inconsistency. Electronic searches of five databases and four online guideline repositories were performed. RA management CPGs were eligible for inclusion if they were written in English and published between January 2015 and February 2022; focused on adults ≥ 18 years of age; met the criteria of a CPG as defined by the Institute of Medicine; and were rated as high quality on the Appraisal of Guidelines for Research and Evaluation II instrument. RA CPGs were excluded if they required additional payment to access; only addressed recommendations for the system/organization of care and did not include interventional management recommendations; and/or included other arthritic conditions. Of 27 CPGs identified, 13 CPGs met eligibility criteria and were included. Non-pharmacological care should include patient education, patient-centered care, shared decision-making, exercise, orthoses, and a multi-disciplinary approach to care. Pharmacological care should include conventional synthetic disease modifying anti-rheumatic drugs (DMARDs), with methotrexate as the first-line choice. If monotherapy conventional synthetic DMARDs fail to achieve a treatment target, this should be followed by combination therapy conventional synthetic DMARDs (leflunomide, sulfasalazine, hydroxychloroquine), biologic DMARDS and targeted synthetic DMARDS. Management should also include monitoring, pre-treatment investigations and vaccinations, and screening for tuberculosis and hepatitis. Surgical care should be recommended if non-surgical care fails. This synthesis offers clear guidance of evidence-based RA care to healthcare providers. TRIAL REGISTRATION: The protocol for this review was registered with Open Science Framework ( https://doi.org/10.17605/OSF.IO/UB3Y7 ).
系统评价评估类风湿关节炎(RA)管理临床实践指南(CPG)的质量,并提供高质量 CPG 建议的综合信息,突出一致性和不一致性的领域。对五个数据库和四个在线指南存储库进行了电子检索。符合以下标准的 RA 管理 CPG 有资格入选:用英语撰写且发表于 2015 年 1 月至 2022 年 2 月之间;针对年龄≥18 岁的成年人;符合医学研究所定义的 CPG 标准;且在评估研究和评估指南 II 工具中被评为高质量。如果 CPG 需要额外付费才能获取;仅针对系统/组织护理建议,不包括干预管理建议;以及/或包括其他关节炎疾病,则将其排除在外。在确定的 27 项 CPG 中,有 13 项符合入选标准并被纳入。非药物治疗应包括患者教育、以患者为中心的护理、共同决策、运动、矫形器和多学科护理方法。药物治疗应包括常规合成疾病修饰抗风湿药物(DMARDs),甲氨蝶呤作为一线选择。如果单一疗法常规合成 DMARDs 未能达到治疗目标,应随后采用联合疗法常规合成 DMARDs(来氟米特、柳氮磺胺吡啶、羟氯喹)、生物 DMARDs 和靶向合成 DMARDs。管理还应包括监测、治疗前检查和疫苗接种,以及结核病和肝炎筛查。如果非手术治疗失败,应推荐手术治疗。该综合信息为医疗保健提供者提供了基于证据的 RA 治疗的明确指导。试验注册:本综述的方案已在开放科学框架(https://doi.org/10.17605/OSF.IO/UB3Y7)上注册。